How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

23,013 results for

Breast Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer P Pertuzumab for adjuvant treatment of ertuzumab for adjuvant treatment of HER2-positiv HER2-positive early stage breast cancer e early stage breast cancer T echnology appraisal guidance Published: 20 March 2019 nice.org.uk/guidance/ta569 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

2. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) (PubMed)

An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) Journals Library (...) An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} After conservative breast surgery for early breast cancer, targeted intra-operative radiotherapy was non-inferior in terms of local

Full Text available with Trip Pro

2016 NIHR HTA programme

3. Observational study: Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality

Observational study: Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality Article Text Diagnosis

2017 Evidence-Based Medicine (Requires free registration)

4. Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women

Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material (...) Cancer American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women Variant 1: Newly diagnosed. Initial workup. Rule out bone metastases. Radiologic Procedure Rating Comments RRL* FDG-PET/CT whole body 2 ???? Tc-99m bone scan whole body 1 ??? X-ray skeletal survey 1 ??? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually

2019 American College of Radiology

5. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO (...) .19.00945 Journal of Clinical Oncology - published online before print May 31, 2019 PMID: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx , MD, PhD 1 x Fabrice Andre ; , MD 2 x Nofisat Ismaila ; , MD, PhD 3 x N. Lynn Henry ; , PhD 2 x Mark R. Somerfield ; , MD 4 x Robert C. Bast ; , PhD 5 x William Barlow ; 6 x Deborah E. Collyar ; , MD 7 x M. Elizabeth Hammond

2019 American Society of Clinical Oncology Guidelines

6. Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness

Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness | CADTH.ca Find the information you need Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost (...) -Effectiveness Published on: October 16, 2017 Project Number: RC0934-000 Product Line: Research Type: Other Diagnostics Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical utility of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence risk in women with early stage breast cancer? What is the comparative cost-effectiveness of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Intraoperative Radiotherapy for Early Stage Breast Cancer

Intraoperative Radiotherapy for Early Stage Breast Cancer 1 Public Summary Document Application No. 1429 – Targeted Intraoperative Radiotherapy for Early-Stage Breast Cancer Applicant: Regional Health Care Group Date of MSAC consideration: MSAC 69 th Meeting, 6-7 April 2017 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting extension of the Medicare Benefits Schedule (MBS) item (...) for Intraoperative Radiotherapy (IORT) for early-stage breast cancer to include services delivered using the Xoft® Axxent® (California, USA) device was received by the Department of Health from the Regional Health Care Group. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC did not support public funding of targeted intraoperative radiotherapy (IORT) using the Xoft® Axxent® device

2017 Medical Services Advisory Committee

8. Adjuvant systemic therapy for early stage (lymph node negative and lymph node positive) breast cancer

Adjuvant systemic therapy for early stage (lymph node negative and lymph node positive) breast cancer CLINICAL PRACTICE GUIDELINE BR-014 Version 5 Adjuvant Systemic Therapy for Early Stage (Lymph Node Negative and Lymph Node Positive) Breast Cancer Effective Date: April, 2018 CLINICAL PRACTICE GUIDELINE BR-014 Version 5 Page 2 of 11 Copyright © (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This material may (...) score:* higher risk 3-5 * Examples: Prosigna TM , OncotypeDx® 6 CLINICAL PRACTICE GUIDELINE BR-014 Version 5 Page 4 of 11 Table 2. Genomic Testing for Systemic Therapy Decision Making* 3-5 Inclusion Criteria Exclusion Criteria • Patient is medically fit to receive adjuvant breast cancer chemotherapy AND • Has early stage resected lymph node negative (including N0i+) or N1mi AND • Either grade 2 or grade 3 invasive breast cancer • Patients unwilling to consider or are medically unfit to receive

2016 CPG Infobase

9. A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer. (PubMed)

A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer. To systematically evaluate the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis (SLNM) versus patients with stage IIIb/c or IV breast cancer, so as to provide evidence for clinical practice and research.Computer retrieval from PubMed, Cochrane Libratory, CNKI (China National (...) Knowledge Infrastructure), CBM and Wanfang Database with the assistance of other retrieval tools. All the studies evaluating the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer were collected. Quality assessment was performed for the included data based on the quality assessment criteria appropriate for this study. Meta-analysis was performed using RevMan 5.3 software.A total of four references (1277

Full Text available with Trip Pro

2017 Chronic diseases and translational medicine

10. Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer (PubMed)

Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer Breast cancer is a heterogeneous disease. The purpose of adjuvant therapy for early-stage breast cancer is to provide maximum benefit with minimum side effects and not to under-treat or over-treat. The clinical progresses of patients with the same clinical and pathological characteristics who are given similar treatments may show major differences. This fact indicates that the prognostic (...) in addition to endocrine treatment. Several new gene expression analysis studies targeted at gaining the ability to determine drug selection in chemotherapy, endocrine treatment and neo-adjuvant therapy are also currently ongoing. The staging system for new breast cancer that is to be published in the year 2018 also includes gene expression analyses within the prognostic panel and the stage changes depending on the result. The statement 'Treat the patient, not the disease.' is becoming increasingly

Full Text available with Trip Pro

2017 European journal of breast health

11. Breast Cancer Beliefs as Potential Targets for Breast Cancer Awareness Efforts to Decrease Late-Stage Presentation in Uganda (PubMed)

Breast Cancer Beliefs as Potential Targets for Breast Cancer Awareness Efforts to Decrease Late-Stage Presentation in Uganda To assess breast cancer beliefs in Uganda and determine whether these beliefs are associated with factors potentially related to nonparticipation in early detection.A survey with open- and close-ended items was conducted in a community sample of Ugandan women to assess their beliefs about breast cancer. Linear regression was used to ascertain associations between breast (...) cancer beliefs and demographic factors potentially associated with early detection, including socioeconomic factors, health care access, prior breast cancer knowledge, and personal detection practices.Of the 401 Ugandan women surveyed, most had less than a primary school education and received medical care at community health centers. Most women either believed in or were unsure about cultural explanatory models for developing breast cancer (> 82%), and the majority listed these beliefs as the most

Full Text available with Trip Pro

2017 Journal of global oncology

12. Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors (PubMed)

Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors Few definitive treatment options exist for elderly patients diagnosed with early stage breast cancer who are medically inoperable or refuse surgery. Historical data suggest very poor local control with hormone therapy alone. We examined the dosimetric feasibility of hypofractionated radiation therapy using (...) stereotactic ablative radiotherapy (SABR) and proton beam therapy (PBT) as a means of definitive treatment for early stage breast cancer.Fifteen patients with biopsy-proven early stage breast cancer with a clinically visible tumor on preoperative computed tomography scans were identified. Gross tumor volumes were contoured and correlated with known biopsy-proven malignancy on prior imaging. Treatment margins were created on the basis of set-up uncertainty and image guidance capabilities of the three

Full Text available with Trip Pro

2018 Advances in radiation oncology

13. Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer (...) with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Published on: June 29, 2016 Project Number: RA0855-000 Product Line: Research Type: Other Diagnostics Report Type: Reference List Result type: Report Question In the adjuvant treatment setting, what is the clinical effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

14. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200 (...) /JCO.2017.74.0472 Journal of Clinical Oncology - published online before print July 10, 2017 PMID: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update x Ian Krop , x Nofisat Ismaila , x Fabrice Andre , x Robert C. Bast , x William Barlow , x Deborah E. Collyar , x M. Elizabeth Hammond , x Nicole M. Kuderer , x Minetta C. Liu , x Robert G. Mennel , x

Full Text available with Trip Pro

2017 American Society of Clinical Oncology Guidelines

15. Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients? (PubMed)

Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients? Imaging findings can be affected by histopathological characteristics, such as breast cancer subtypes. The aim was to determine whether the diagnostic performance, in particular negative predictive value (NPV), of axillary US differs per subtype of breast cancer.All patients diagnosed between 2008 and 2016 in our hospital with primary invasive breast cancer (...) and an axillary US prior to axillary surgery were included. Histopathology of axillary surgery specimens served as gold standard. The NPV, sensitivity, specificity, positive predictive value (PPV) and accuracy of the axillary US were determined for the overall population and for each subtype (ER+/PR+HER2-,HER2+, triple negative tumors). The Chi-square test was used to determine the difference in diagnostic performance parameters between the subtypes.A total of 1094 breast cancer patients were included

2019 European Journal of Surgical Oncology

16. Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial. (PubMed)

Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial. We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in HER2-positive early-stage breast (...) cancer.Women (N=2840) with early-stage HER2-positive breast cancer who had completed trastuzumab-based adjuvant therapy were randomly assigned to neratinib 240 mg/day or placebo for 12 months. HRQoL was an exploratory endpoint. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQol 5-Dimensions (EQ-5D) questionnaires at baseline and months 1, 3, 6, 9, and 12. Changes from baseline were compared using analysis of covariance with no imputation for missing values

2019 Annals of oncology : official journal of the European Society for Medical Oncology

17. Comparison of Pathological Prognostic Stage and Anatomic Stage Groups According to the Updated Version of the American Joint Committee on Cancer (AJCC) Breast Cancer Staging 8th Edition (PubMed)

Comparison of Pathological Prognostic Stage and Anatomic Stage Groups According to the Updated Version of the American Joint Committee on Cancer (AJCC) Breast Cancer Staging 8th Edition BACKGROUND We compared pathological prognostic stage (PPS) with anatomic stage (AS) groups according to the updated version of breast cancer staging of the American Joint Committee on Cancer (AJCC) 8th Edition. MATERIAL AND METHODS We evaluated 353 breast cancer patients initially treated with surgery (...) . AS and PPS were performed by evaluating the pathological data of the patients according to the AJCC 8th Edition breast cancer updated version. Stages and survival rates between the 2 staging systems were evaluated and compared. Disease-free survival (DFS) and disease-specific survival (DSS) were calculated according to both staging systems using Kaplan-Meier test. After the PPS change was made in each AS group, 10-year DFS and 10-year DSS of the changed groups were compared using the chi-square test

Full Text available with Trip Pro

2018 Medical science monitor : international medical journal of experimental and clinical research

18. Combined positron emission tomography and magnetic resonance imaging for breast cancer staging

Combined positron emission tomography and magnetic resonance imaging for breast cancer staging Combined positron emission tomography and magnetic resonance imaging for breast cancer staging Combined positron emission tomography and magnetic resonance imaging for breast cancer staging HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) .. Combined positron emission tomography and magnetic resonance imaging for breast cancer staging. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Although positron emission tomography (PET) provides information about glucose metabolism, cellular proliferation, and cellular receptor expression, it has limited spatial resolution. Hybrid PET/magnetic resonance imaging (MRI) scanners have recently become available. Compared with PET

2016 Health Technology Assessment (HTA) Database.

19. Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer Ä neoadjuvant therapy

Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer Ä neoadjuvant therapy Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation NIHR HSRIC. Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age and have already gone through the menopause. There are many types of breast cancer. Triple negative is a form of breast cancer

2016 Health Technology Assessment (HTA) Database.

20. A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer

A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer To systematically evaluate the safety, feasibility, and effect of exercise among women with stage II+ breast cancer.CINAHL, Cochrane, Ebscohost, MEDLINE, Pubmed, ProQuest Health and Medical Complete, ProQuest Nursing and Allied Health Source, Science Direct and SPORTDiscus were searched for articles published before March 1, 2017.Randomized, controlled, exercise trials (...) involving at least 50% of women diagnosed with stage II+ breast cancer were included.Risk of bias was assessed and adverse event severity was classified using the Common Terminology Criteria. Feasibility was evaluated by computing median (range) recruitment, withdrawal, and adherence rates. Meta-analyses were performed to evaluate exercise safety and effects on health outcomes only. The influence of intervention characteristics (mode, supervision, duration and timing) on exercise outcomes were also

2019 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>